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Abstract
 
All thymically selected T cells are inherently cross-reactive, yet many data indicate a fine speci-
ficity in antigen recognition, which enables virus escape from immune control by mutation in
infections such as the human immunodeficiency virus (HIV). To address this paradox, we ana-
lyzed the fine specificity of T cells recognizing a human histocompatibility leukocyte antigen
(HLA)-A2–restricted, strongly immunodominant, HIV gag epitope (SLFNTVATL). The majority
of 171 variant peptides tested bound HLA-A2, but only one third were recognized. Surprisingly,
one recognized variant (SLYNTVATL) showed marked differences in structure when bound
to HLA-A2. T cell receptor (TCR) recognition of variants of these two peptides implied that
they adopted the same conformation in the TCR–peptide–major histocompatibility complex
(MHC) complex. However, the on-rate kinetics of TCR binding were identical, implying that
conformational changes at the TCR–peptide–MHC binding interface occur after an initial
permissive antigen contact. These findings have implications for the rational design of vaccines
targeting viruses with unstable genomes.
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Introduction
 
Current information on the extent of T cell cross-reactivity
presents a paradox; there is evidence that T cells are
broadly cross-reactive (1–4), but other data show narrow
specificities (5–11). The balance achieved between these
opposing characteristics is particularly pertinent to antiviral
immunity, where antigenic variation may result in poor T
cell recognition and profoundly affect the outcome of an
infection (12). Although there are clear examples of virus
escape from T cell immune responses by point mutations in
key epitopes (13–18), it is possible that such escape is the
exception, as most of the examples involve escape by a subset
of peptide variants that fail to bind to the presenting HLA
molecule. As T cells that cross-react to more than one sub-
type of a virus such as HIV have been described previously
(19–23), there is intense debate about whether to match
HIV vaccines and virus sequences (24, 25).
Cross-reactivity is a characteristic of T cell recognition
because all T cells that reach the periphery must have
bound previously to at least one combination of self-peptide
and major histocompatibility complex molecule to have
been positively selected in the thymus (1, 2). Furthermore,
there are examples of mature T cells capable of cross-reacting
with different peptide–MHC complexes; i.e., Epstein Barr
virus EBNA3-HLA-B8–specific cytotoxic T cells that cross-
react with various self peptides presented by HLA-B35 (3).
Examples are also known for MHC class II–restricted CD4
 
 
 
T cells and such cross-reactivity may underlie autoimmune
disease (4). In contrast, fine specificity studies of T cell
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clones, in functional assays, have shown great sensitivity to
epitope variation. In some cases, the antigens were closely
related to self (5–7), so tolerance to the self epitopes might
have preselected T cells that react to only very limited
epitope variants. Similarly, T cells responding to peptide
immunogens (8) could show restricted specificity because
the antigen is suboptimal. However, three studies of hu-
man CD8
 
 
 
 
 
T cell responses to natural viral antigens (9–11)
show that immunodominant CD8
 
 
 
 T cells are finely re-
stricted in epitope specificity.
To assess systematically the extent of cross-reactivity in
clinically relevant CD8
 
 
 
 T cells, we focused on the re-
sponse to a highly immunodominant HLA-A2–restricted
and naturally highly variable epitope, SLFNTVATL, in
HIV gag p17. We explored sensitivity of this T cell re-
sponse to immune escape by single amino acid change. As
 
 
 
40% of the population express HLA-A2, the sensitivity of
this dominant T cell response to HIV variation could have
a significant impact on the control of HIV infection.
We show that most single amino acid changes, when ap-
plied to this peptide sequence, abolish functional recognition
for both specific T cell clones and for uncloned T cell re-
sponses in the blood of different HIV-infected patients. Al-
though many altered peptides were not recognized, the T
cells reacted to both of the common A and B subtype vi-
rus variants, which differ at position three, phenyalanine
(SLFNTVATL) and tyrosine (SLYNTVATL), respectively;
cross-reactivity to these two variants is typical of 
 
 
 
50% of T
cell responses in the population (26). However, when we de-
termined the crystal structures of HLA-A2 with the SLFNT-
VATL and SLYNTVATL peptides, we found a striking
structural difference, resulting from a significant change in
the conformation of the bound peptide. The ability of T cells
to cross-react despite this large difference appeared incom-
patible with the observed sensitivity of the T cell recognition
to other very small changes in sequence, which would typi-
cally equate to relatively small chemical or steric differences
at the TCR binding surface. We showed that the T cells
show similar patterns of recognition of further single amino
acid variants of these two peptides. In combination, these
data suggest that, ultimately, the T cells recognize a confor-
mation common to both peptides and, therefore, that one or
both change conformation on TCR binding. Kinetic and
thermodynamic studies of TCR interaction with these two
peptide–HLA-A2 molecules imply that the conformational
change required for the TCR and the peptide-MHC
(pMHC) to dock in a stable complex probably occurs after
the initial phase of TCR binding. Thus, first contact between
TCR and pMHC may tolerate marked variation in peptide
structure and sequence, but once any energetically favorable
conformational adjustments have been generated, the func-
tional TCR interaction is very specific, requiring a high level
of conservation in the detailed features of the pMHC.
 
Materials and Methods
 
Cell Culture. 
 
HLA-A2–restricted, HIV-1–specific CTLs were
cloned by limiting dilution of PBMCs of infected donors. Clones
recognized both subtypes A and B of the HLA-A2–restricted gag
p17 epitope, SLFNTVATL and SLYNTVATL, respectively.
 
Peptides. 
 
Single amino acid variants of SLFNTVATL, an
HLA-A2–restricted epitope from the HIV p17 gag matrix pro-
tein, were synthesized using the Advanced Chemtech automated
synthesizer. Peptides were checked for purity by HPLC. Most
peptides (156 out of 171) showed 
 
 
 
95% purity.
 
ELISPOT Assay.
 
ELISPOT plates (Millipore) were coated
with anti–human IFN-
 
 
 
 Ab (Mabtech) for 2 h at 37
 
 
 
C. The
plates were washed six times with PBS 0.05% Tween and incu-
bated for 1 h with R10 at room temperature. 50 
 
 
 
l HLA-A2 B
cells at 10
 
5
 
 cells/ml were added to each well in duplicate. Before
adding to wells, B cells were prepulsed with each variant peptide
at 2 
 
 
 
M final concentration for 20 min at 37
 
 
 
C. Next, 50 
 
 
 
l
CTL clones at 4 
 
 
 
 10
 
3
 
 cells/ml were added to a final volume of
100 
 
 
 
l. The plates were incubated overnight at 37
 
 
 
C. After cell
removal, a second biotinylated Ab to human IFN-
 
 
 
 was added
and incubated at room temperature for 2 h. After washing, the
plates were developed with streptavidin–alkaline phosphatase (Mab-
tech) and colorimetric substrate. Spot-forming units (SFU) were
counted using an automated ELISPOT reader. Background counts
for negative control wells without peptides were always 
 
 
 
5
spots/well. Results were expressed as percentage of SFU com-
pared with the index peptide (SLFNTVATL).
 
Cytotoxicity Assay.
 
EBV-transformed HLA-A201 B cells were
labeled with 
 
51
 
Cr and resuspended to 10
 
5
 
 cells/ml. 50 
 
 
 
l were
transferred to each well of a 96-well plate containing 16.7 
 
 
 
l of
peptide diluted in RPMI 1640. Variant peptides were initially
tested at concentrations of 10, 2, 1, 0.1, 0.01, and 0.001 
 
 
 
M. Af-
ter 30 min at 37
 
 
 
C, CTL clones were added in 100 
 
 
 
l R10 to
give an E/T ratio of 5:1. The plates were incubated at 37
 
 
 
C for
5 h. 30 
 
 
 
l of the supernatant was collected, and 150 
 
 
 
l of scintilla-
tor fluid was added to each well. 
 
51
 
Cr release was counted in du-
plicate using a Microbeta counting program. Spontaneous release
was 
 
 
 
25% of detergent release. Percent specific lysis was calcu-
lated as the following: 100 
 
 
 
 [(experimental release 
 
 
 
 spontane-
ous release) / (detergent release 
 
 
 
 spontaneous release)]. Results
were expressed as percent of lysis seen with the SLFNTVATL
peptide.
 
TCR Sequencing and Cloning. 
 
RNA was extracted using Tri-
Reagent from CTL clones and subjected to an RT-PCR amplifi-
cation technique with a switching mechanism at the 5
 
 
 
 end of the
RNA transcripts (27). This was performed with C-region 
 
 
 
primer: TCRAC, 5
 
 
 
-GTCCATAGACCTCATGTCTAGCA-
CAG-3
 
 
 
; and a C-region 
 
 
 
 primer: TCRBC, 5
 
 
 
-ATTCAC-
CCACCAGCTCAGCTCCACG-3
 
 
 
. Sequencing was performed
with gel-purified PCR products using the dideoxy chain-termi-
nation method on a Megabase 1000. Specific primers were de-
signed to clone the G10 and T5-004 TCR 
 
 
 
 and 
 
 
 
 chains into
the 
 
Escherichia
 
 
 
coli
 
 expression vector Pett22b
 
 
 
 (Novagen) without
the native leader peptide sequences, and the 
 
 
 
 chain was cloned
in frame with the COOH-terminal vector His
 
6
 
 tag. Residues 
 
 
 
threonine 166 and 
 
 
 
 threonine 174 were mutated to cysteines.
 
Clonotype Analysis. 
 
PBMCs were stained with PE-conju-
gated SLFNTVATL– or SLYNTVATL–HLA-A2 tetramers, and
fluorochrome-conjugated antibodies specific for CD3 and CD8.
Tetramer
 
 
 
 
 
CD8
 
 
 
 T cells (3,000 cells each) were sorted using a
FACSDiVA (Becton Dickinson) directly into collection tubes
containing 100 
 
 
 
l RNAlater (Ambion). mRNA was extracted
and template switch-anchored RT-PCR was performed using a
TCRBC primer to obtain full-length TCRBVDJ PCR products
as described previously (28). PCR products were ligated into the
pGEMT Easy Vector (Promega) and used to transform compe- 
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tent bacteria. Colonies were selected, amplified by PCR with
standard M13 primers, and sequenced as described previously
(28). Sequences were analyzed using Sequencher.
 
Protein Expression, Refolding, and Purification. 
 
Residues 1–278
of the HLA-A2 heavy chain, cloned in Pett22b
 
 
 
, were expressed
in BLR (Novagen) 
 
E. coli
 
 as inclusion bodies, refolded, and puri-
fied with the HIV-1 p17 peptides SLFNTVATL or SLYNT-
VATL and 
 
 
 
-2 microglobulin as described previously (29). For
soluble G10 TCR production, residues 1–211 and 1–242 from
the 
 
 
 
 and 
 
 
 
 chains, respectively, were cloned into Pett22b
 
 
 
(Novagen), and the protein was expressed in BLR strain 
 
E. coli
 
(Novagen) as inclusion bodies. Soluble TCR protein was re-
folded and purified as described previously (30). Soluble G10
TCR was diluted to 0.106, 0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40,
and 80 
 
 
 
M in HBS buffer (Biacore) for the surface plasmon reso-
nance experiment.
 
Crystallization and Data Collection. 
 
All crystallizations were
performed using the hanging drop vapor diffusion technique.
Single HLA-A2–SLFNTVATL or HLA-A2–SLYNTVATL crys-
tals grew at 4
 
 
 
C at a final concentration of 10 mg/ml in 14% PEG
6000 50 mM MES, pH 6.5, to dimensions of 
 
 
 
150 
 
 
 
m 
 
  
 
80
 
 
 
m 
 
 
 
 40 
 
 
 
m. Crystals were harvested and soaked briefly and se-
quentially in reservoir solutions containing 10 and 20% glycerol,
flash cooled, and maintained at 100 K in a cryostream (Oxford
Cryosystems). Two high resolution datasets were collected at sta-
tion 14.2 of the Synchrotron Radiation Source using an ADSC-
q4 (Area Detector Systems Corporation) charged-coupled device
detector. The crystals belonged to space group P1, and datasets
were auto-indexed and integrated with the program DENZO
(31), followed by scaling with the program SCALEPACK (31);
the results are summarized in Table I.
 
Structure Determination, Refinement, and Analysis. 
 
Crystal
structures were determined by molecular replacement using the
program EPMR (32). For the HLA-A2–SLFNTVATL and the
HLA-A2–SLYNTVATL diffraction data, the asymmetric dimer
of heavy chains and 
 
 
 
2m domains from a high resolution crystal
structure of HLA-A2–influenza matrix epitope (unpublished
data) was used as the search probe (with peptide coordinates
omitted) and yielded unambiguous solutions of R
 
cryst
 
 of 
 
 
 
45%
(R
 
free
 
 
 
 
 
46%) for data between 30 and 4Å. A Fo-Fc difference
map revealed clearly the presence of the antigenic peptides. The
difference in peptide conformation between HLA-A2–SLFNT-
VATL and HLA-A2–SLYNTVATL was unambiguous.
Using the CNS program (33) HLA-A2–SLFNTVATL and
HLA-A2–SLYNTVATL were subjected to several rounds of
rigid body refinement of individual domains (
 
 
 
1, 
 
 
 
2, 
 
 
 
3, 
 
 
 
2m),
and the peptides were modeled into Fo-Fc difference density
maps using program O (34). Further rounds of refinement were
performed using standard CNS protocols for bulk solvent correc-
tion and overall anisotropic B-factor scaling, positional refine-
ment, simulated annealing, and individual B-factor refinement.
Manual refitting of the models was performed using O, and water
molecules were added based on peaks that were at least 3.0 
 
 
 
 in
height in Fo-Fc density maps. Program REFMAC (35) was used
for a final round of refinement with program ARP/wARP to add
an additional set of bound water molecules (36). Structural super-
positions were performed using program SHP (37). Fig. 4 was
prepared using program BobScript (38).
 
T2 Peptide Binding Assay. 
 
A TAP-deficient T2 cell line was
used to assess the ability of HLA-A2 to bind each of the variant
peptides (39, 40). In brief, 10
 
5 
 
T2 cells were incubated with 300
 
 
 
M of each of the peptide variants overnight for 16 h at 37
 
 
 
C in
serum-free RPMI 1640 medium in flat-bottom 96-well plates.
Cells were transferred to round-bottom 96-well plates the next
day and washed with PBS. Cells were stained for HLA-A2 by im-
munofluorescence using FITC-labeled mAB BB7.2 (anti–HLA-
A2; BD Biosciences). Results were determined by FACS sorting.
 
Surface Plasmon Resonance. 
 
Surface plasmon resonance studies
were performed using a BIAcore 2000 (Biacore AB) as described
previously (41). HLA-A2–SLFNTVATL and HLA-A2–SLYNT-
VATL were enzymatically biotinylated on COOH-terminal BirA
recognition and immobilized to CM5 sensor chips via covalently
coupled streptavidin (41). Kinetic constants were derived using
the curve-fitting facility of the BIAevaluation program (Version
3.0; BIAcore) and rate equations were derived from the simple
1:1 Langmuir binding model (A 
 
  
 
B
 
→
 
AB). Other curve fitting
was performed in Origin version 5 (MicroCal). Equilibrium ther-
modynamic constants were obtained by measuring the 
 
 
 
G
 
o
 
 over
a range of temperatures and fitting to these data the nonlinear
form of the van’t Hoff equation (42),
where T is the temperature in Kelvin (K); To is an arbitrary refer-
ence temperature (e.g., 298.15 K); 
 
 
 
G
 
 
 
 is the standard free energy
of binding at T (kcal.mol
 
 
 
1
 
) and is calculated from the equilibrium
dissociation constant (Kd); 
 
 
 
H
 
To
 
 is the enthalpy change upon
binding at To (kcal.mol
 
 
 
1
 
); 
 
 
 
STo is the standard state entropy
change upon binding at To (kcal.mol 1.K 1); and  Cp is the
change in heat capacity (kcal.mol 1.K 1) and is assumed to be tem-
perature independent.
Thermodynamic constants for the transition state were deter-
mined by measuring the rate constants over a range of tempera-
tures (43). According to transition state theory,
where krate is a first order rate constant (e.g., either koff or kon C 
where C  is the standard state concentration [1 M]); kB is the Boltz-
mann constant (3.3   10 24 cal.K 1); h is the Plank constant (1.6  
10 34 cal.s); R is the gas constant (2 cal.K 1mol 1); and  ‡H and
 ‡S are the enthalpy and standard state entropy of activation, re-
spectively.  ‡H and  ‡S are determined from the slope and inter-
cept, respectively, of a plot of ln(krate/T) against 1/T.
Online Supplemental Material. Figs. S1 and S2 show peptide ti-
tration assays which were performed for the index peptide and
peptide variants in the ELISPOT assay over a range from 10 to
0.008   M, and in the chromium release assay over a range of
10 5–10 11 M, respectively, to determine the optimal peptide con-
centration. The overall recognition patterns to all 171 peptide vari-
ants measured in the cytotoxicity assay for the two clones are sum-
marized in Fig. S3. Functional correlation between the responses to
the peptide variants in the ELISPOT and cytotoxicity studies is
shown in Fig. S4. Online supplemental material is available at http:
//www.jem.org/cgi/content/full/jem.20041251/DC1.
Results
Fine Specificity of SLFNTVATL Recognition by CD8  T
Cells. We selected two T cell clones, specific for the
SLFNTVATL peptide presented by HLA-A2, that ex-
pressed completely different T cell receptors: clone G10
carried a V  28.1 (CDR3  -loop region sequence CAV-
LGNSGNTPLV) and V  5.1 (CDR3  -loop region se-
∆G°∆ HTo T ∆STo ∆Cp TT o – () T ∆Cp ln T
To
------ ⎝⎠
⎛⎞ × × – + × , – =
ln
krate
T
-------- ⎝⎠
⎛⎞ln
kB
h
----- ⎝⎠
⎛⎞∆‡S
R
--------- ∆‡H
RT
----------- , – + =Fine Specificity of HIV-specific T Cells 1458
quence CASSFDAEAF) TCR, and clone T5-004 used V 
2.1 (CDR3  -loop region sequence CAFPSGYALN) and
V  2.3 (CDR3  -loop region sequence CATSSTGTGG-
GETQY). These clones were tested in the ELISPOT assay
with 171 variant peptides of the SLFNTVATL epitope,
each differing by one amino acid from the index peptide
sequence. Thus, all possible single amino acid changes to
the SLFNTVATL epitope were tested for recognition. The
results (Fig. 1) indicate that less than one third of these sin-
gle amino acid variant peptides were recognized, with sim-
ilar patterns of response for the two clones. Virtually identi-
cal results were obtained in a CTL lysis assay (Figs. S1 and
S2, available at http://www.jem.org/cgi/content/full/jem.
20041251/DC1). For both assays, the peptides were ti-
trated and the concentrations used were chosen to be the
lowest that gave maximal recognition of the parent peptide
(Figs. S3 and S4, available at http://www.jem.org/cgi/
content/full/jem.20041251/DC1). It is noteworthy that,
like the total response in approximately half of HLA-A2 
HIV-infected people, these T cell clones cross-reacted be-
tween the A subtype SLFNTVATL and B subtype SLYN-
TVATL sequences.
To determine to what extent failure of the peptide to
bind HLA-A2 contributed to nonrecognition by the T
cells, we titred each peptide for its ability to stabilize surface
expression of HLA-A2 on the T2 cell line (39, 40). The
SLFNTVATL and SLYNTVATL peptides reached maxi-
mum HLA-A2 stabilization at 200–300  M. Other pep-
tides tended to bind less well but the level of HLA-A2 ex-
pression observed at peptide concentration of 300  M gave
a qualitative assessment of whether a peptide bound (Fig.
2). Most (74.5%) peptides bound to a measurable extent
and 29 out of the 51 that gave undetectable binding were
altered at the main anchor positions, 2 and 9 for peptides
presented by HLA-A2. 65.5% of the peptides that were
seen by neither clone gave detectable binding ( 5% in-
creased expression compared with the index peptide), sug-
gesting that nonrecognition could be attributed to inade-
Table I.  Crystallographic Statistics
SLFNTVATL SLYNTVATL
Data collection
Space group P1 P1
Unit cell
Dimensions (Å) (a, b, c) 47.9, 60.7, 71.1 48.1, 60.1, 71.2
Angles ( ) ( ,  ,  ) 81.8, 76.2, 77.7 82.0, 76.2, 78.1
Source SRS BM14-2 SRS BM14-2
Resolution (Å)
(highest resolution shell)
20   1.6 (1.66   1.60)a 20   1.6 (1.66   1.60)a
Measured reflections 528,451 518,711
Unique reflections 99,884 101,373
Completeness (%) 93.5 (64.6)a 92.4 (58.8)a
I/  (I) 14.0 (1.7)a 21.2 (2.1)a
Rmerge (%)b 6.0 (45)a 3.5 (31)a
Refinement statistics
Resolution range (Å) 20   1.6 (1.66   1.60)a 20   1.6 (1.66   1.60)a
Rcryst
c 21.0 21.5
Rfree
d 24.1 24.1
No. of residues 768 768
No. of water molecules 755 768
Rms deviation from ideality
Bond lengths (Å) 0.015 0.016
Bond angles ( ) 1.54 1.62
Ramachandran plot (%)
(favored, allowed, generous, disallowed)
(91.3, 8.4, 0.3, 0.0) (93.5, 7.2, 0.3, 0.0)
aNumbers in parentheses correspond to the outermost shell of data.
bRmerge    hkl| I    I  | /  hkl | I | where I is the intensity of unique reflection hkl and  I  is the average over symmetry-related observations
of unique reflection hkl.
cRcryst     | Fobs   Fcalc | /   | Fobs | where Fobs and Fcalc are the observed and calculated structure factors, respectively.
dRfree is calculated as for Rcryst but using 5.0% of reflections sequestered before refinement.Lee et al. 1459
quate contact of bound peptide with the T cell receptor. 17
peptides (S1P, L2C, L2I, L2K, L2Q, L2T, V6I, A7G, A7L,
T8S, T8V, L9A, L9E, L9F, L9N, L9P, L9Q) out of the 51
that gave undetectable binding were seen by at least one T
cell clone, consistent with T cells’ ability to respond to very
low numbers of epitope peptide on MHC molecules (44,
45). Thus, much of the nonrecognition by T cells of pep-
tides altered at residues 3–8 represents failure of the T cell
receptor to engage with a bound peptide.
Although the clones from two different donors were
thought to be representative, we also tested uncloned
PBMCs from two further HIV  donors (Fig. 3). These re-
sponses were similarly highly sensitive to variation in the
epitope, but showed cross-reactivity to the A subtype
SLFNTVATL and B subtype SLYNTVATL epitopes (Fig.
3, A and B). The clonality of this response was assessed by
sorting SLFNTVATL- and SLYNTVATL-specific T cells
from one of these donors using the respective tetramers and
sequencing the TCRB CDR3 regions using unbiased an-
chored RT-PCR (28). We found that the SLFNTVATL-
specific T cells comprised two clones, defined by different
TCR BV sequences, one more frequent than the other
(Fig. 3 C). The SLYNTVATL-specific T cells comprised
one clone, which was identical in its expressed TCRB lo-
cus, to the dominant SLFNTVATL-specific clone (Fig. 3
C). Thus, the two clones dominating this response showed
very fine specificity when confronted with each of the pep-
tide variants, similar to results with the cloned T cells.
Structure of HLA-A2 with SLFNTVATL and SLYNT-
VATL. We embarked on structural analysis of HLA-A2–
SLFNTVATL and HLA-A2–SLYNTVATL to provide
structural contexts for interpretation of the functional ef-
fects of single amino acid changes to the peptides (26). We
succeeded in crystallizing HLA-A2 bound to both peptides
and determined the two crystal structures at high resolution
(1.6 Å).
The structure of SLFNTVATL bound to HLA-A2 is
shown in Fig. 4 A. As in previous nonamer peptide–HLA-
A2 structures (46), peptide positions 2 and 9 are major an-
chors, with L2 deeply buried in the B pocket and L9 in
the F pocket, whereas position 3 is a secondary anchor,
with F3 inserted into the D pocket. As reported before,
many variant peptides with single amino acid changes at
residues 3–8 retained the ability to bind HLA-A2, but
were not recognized by T cells. In this region of the
bound SLFNTVATL peptide, the side chains of residues
4, 6, and 8 are highly exposed to solvent (and TCR recog-
nition), the side chains of residues 3 and 7 are partially ex-
posed, and the side chain of residue 5 is orientated down-
Figure 1. Recognition pattern of monosubstituted SLFNTVATL peptide
variants by two different CTL clones. Clones G10 and T5-004 from two
different HIV  donors were tested for their capacity to recognize peptide-
pulsed HLA-A2 B cells by measuring IFN-  secretion in the ELISPOT
assay. Every one of the 20 genetically coded amino acids was substituted
in each of the nine possible positions in the HLA-A2–restricted epitope
SLFNTVATL (total of 171 peptide variants). The residues of the index
peptide SLFNTVATL are listed horizontally at the top of the chart; the
letters along the sides indicate the residues replacing the index residue.
Results were expressed as a ratio of the percentage of SFU as compared
with the index peptide (SLFNTVATL). Responses were graded as corre-
sponding shades in the boxes. This assay was repeated three to five times
for each variant peptide, with each experiment yielding the same pattern
of peptide recognition. Background counts for negative control wells
without peptides were always  5 SFU/well.
Figure 2. Binding of peptide variants to HLA-A2. All 171 single amino
acid substitution peptide analogues of SLFNTVATL were tested for bind-
ing to HLA-A2 using TAP-deficient T2 cells. Results were determined
by flow cytometry analysis. Peptide variants were compared with the in-
dex peptide SLFNTVATL, and results were expressed as a percentage of
the mean fluorescence. Relative binding strengths were graded into the
corresponding shades in the boxes.Fine Specificity of HIV-specific T Cells 1460
ward into the peptide binding groove (Fig. 4, A and B).
The main chain conformation for the central region of
peptides bound to HLA-A2 is highly variable (46), but the
available crystal structures for nonamer peptides bound to
HLA-A2 indicate that it is common for one of the side
chains of residues 5, 6, or 7 to point down into the bind-
ing groove (46–48). Conversely, an absence of stabilizing
contacts between MHC and peptide in this region has
been associated with poor peptide binding affinity (49).
The conformation of SLFNTVATL bound to HLA-A2 is
similar to that of the HIV-1 gp120 epitope TLTSCNTSV
reported by Madden et al. (46, PDB accession code 1HHG;
reference 46).
Similar to a previous, systematic study of the effect of
single amino acid substitutions on T cell recognition of a
peptide–HLA-A2 complex, the nonrecognition of peptides
altered at P3-P8 can result from direct or indirect changes
at the TCR recognition surface (11). On the basis of the
bound structure of the index peptide SLFNTVATL, substi-
tutions at the highly exposed side chains of residues 4, 6,
and 8 may result in direct changes to interactions with
TCRs. However, T cell recognition appears to be equally,
if not more, sensitive to substitutions to the buried side
Figure 3. The recognition pattern of monosubstituted SLFNTVATL peptide
variants by PBMCs from an HIV  patient and clonotype analysis. (A) PBMCs from
an HIV  patient (who was not the donor of either T cell clone) were tested for recognition of SLFNTVATL and single amino acid variants in the ELISPOT
assay. Results were expressed as percentage of SFU as compared with the index peptide. Responses were graded as corresponding shades in the boxes. Back-
ground counts for negative control wells without peptides were always  5 SFU/well. (B) Tetramer staining of SLFNTVATL or SLYNTVATL-specific
CD8  T cells from PBMCs of the HIV  patient. Tetramer  cells were flow cytometrically sorted and subjected to TCRB sequence analysis. (C) TCRB se-
quences of SLFNTVATL and SLYNTVATL-specific CD8  T cells from B and their frequency in the total number of bacterial colonies sequenced.
Figure 4. Structural differences between SLFNTVATL and SLYNT-
VATL peptide conformations in HLA-A2. (A) 2Fo-Fc electron density
for SLFNTVATL and (C) SLYNTVATL peptides are shown as green
chicken wire (contoured at 1.2  ) viewed in profile through the HLA-A2
 2 helix. (B) General side chain orientation for the two peptides as
viewed in profile through the  2 helix. (D) Comparison of SLFNT-
VATL (green) and SLYNTVATL (red) peptide structures by superimpo-
sition of the two binding grooves, illustrating the diametric apposition of
the P5 and P6 side chains of the two peptides. (E) Diagram illustrating the
two different hydrogen-bonding arrangements of the P5 threonine with
the HLA-A2 molecule: (i) The interaction of SLFNTVATL P5 threonine
with R97, and (ii) the interaction of SLYNTVATL P5 threonine with
Q155. These interactions appear to lock the peptides into their discrete
conformations. Hydrogen bonds are denoted as red dashes.Lee et al. 1461
chain of residue 5. In the index peptide, the side chain of
T5 makes a hydrogen bond with arginine at position 97 in
the floor of HLA-A2 groove (Fig. 4 E); the only variant at
this position recognized by the T cells was serine (Fig. 1),
which would be able to make an identical hydrogen bond.
Other P5 variants bound HLA-A2 (Fig. 2), but were not
recognized by the T cells. This would be consistent with a
change in hydrogen bonding of the P5 side chain, causing
changes in the bound conformation of the peptide such
that TCRs specific for the native sequence cannot interact.
On the basis of the first set of peptide–HLA-A2 crystal
structures, Madden et al. (46) suggested that single amino
acid substitutions could alter the entire conformation of the
bound peptide. Subsequent studies have demonstrated that
even subtle changes in anchor residues can change the
pMHC surface (i.e., as in the HLA-B8 HIV-1 gag p17
[24–31] structure, substitution of arginine for lysine at the
position five anchor [50]).
The structure determination of HLA-A2–SLYNTVATL
unexpectedly confirmed that single amino acid substitu-
tions at secondary anchor positions could exert profound
effects on the overall conformation of the SLFNTVATL
peptide. Comparison of the structures of HLA-A2–SLFN-
TVATL and HLA-A2–SLYNTVATL revealed a substan-
tial difference in the conformations of the peptides (Fig. 4).
As a result of a switch in main chain conformation for the
central portion of the SLYNTVATL peptide, the positions
of the T5 and V6 side chains were flipped by  180 de-
grees. The P5 threonine–HLA-A2 R97 hydrogen bond is
exchanged for a hydrogen bond between P5 threonine and
HLA-A2 Q155 (Fig. 4 E). This change in conformation is
not forced by any potential steric clash resulting from the
addition of the side chain hydroxyl group on substitution
of phenylalanine with tyrosine. Instead it appears to be the
result of the changed electrostatic environment of the bind-
ing groove no longer favoring polar interactions with the
P5 threonine over hydrophobic interactions with the P6
valine. The balance of polar and hydrophobic interactions
determining the choice of this conformation for SLYNT-
VATL, in preference to the conformation adopted by
SLFNTVATL, is subtle, but there is no evidence of mixed
conformations for either peptide in the respective crystal
structures. The 1.6-Å resolution of both crystallographic
datasets leaves no doubt that the two peptide structures are
distinct and correct. Both structures were derived from
crystals grown under identical conditions and were of the
same space group (P1) and unit cell dimensions. The crys-
tallographic asymmetric unit contained two copies of the
HLA-A2–peptide molecules with the peptides adopting a
common conformation, and there were no direct lattice
contacts involving the peptides. The HLA-A2–SLFNT-
VATL structure was determined three times: twice in the
P1 space group crystal form to give structure, at pH 6.5 and
pH 7.4 (both to 1.6 Å resolution), and once in a P21 space
group crystal form, at pH 7.4 (1.5-Å resolution with two
molecules in the asymmetric unit; unpublished data). In
each case, the SLFNTVATL peptide clearly adopted ex-
actly the same conformation.
Figure 5. Comparison of clonal responses
to P5 and P6 variants of SLFNTVATL and
SLYNTVATL. Clones G10 and T5-004
were tested for the recognition of single
amino acid substitution peptide analogues of
SLYNTVATL, in which the residues at P5
and P6 were substituted by all of the 19
other amino acids. The P5 and P6 peptide
variants were tested for the capacity to sensi-
tize HLA-matched B cells to induce IFN- 
production in the ELISPOT assay as described
before. Responses were compared relative
to the index peptide SLYNTVATL and
graded into four groups as shown. The
overall recognition patterns to the P5 and
P6 peptide variants of SLYNTVATL and
corresponding SLFNTVATL-derived vari-
ants are nearly identical for the two clones.Fine Specificity of HIV-specific T Cells 1462
T Cell Recognition of Variants at Positions 5 and 6 in
SLFNTVATL and SLYNTVATL. The T cell clones we
used, and approximately half the polyclonal T cell re-
sponses in HIV-infected people with HLA-A2, cross-react
with SLFNTVATL and SLYNTVATL. Given the very
fine specificity requirements for these responses in the rec-
ognition experiments, T cell cross-reactivity for this vari-
ant seemed to be at odds with the crystallographic find-
ings. Therefore, we made and tested, using the two T cell
clones, each of the 38 variants at positions 5 and 6 for
both index peptides. The results show that the patterns of
recognition were identical for clone T5-004 and very
similar for clone G10 (Fig. 5). This implies that the side
chains P5 and P6 are in the same position for T cell recep-
tor interaction for both the P3F and P3Y epitopes. This
could be explained by conformational changes in one or
both peptides upon TCR binding, with the peptides
adopting the same conformation in the TCR–peptide–
MHC complex.
Kinetic Studies of TCR Binding to HLA-A2 Complexed
with SLFNTVATL or SLYNTVATL. Conformational
adjustments are known to occur at the binding interface
when TCR engages pMHC (11, 30, 51–56). Conforma-
tional changes at binding interfaces can either precede or
follow binding, as recently reviewed by Goh et al. (57).
When they precede binding, there is a preexisting equilib-
rium between different conformational isoforms, one of
which is compatible with binding. Because this is usually a
minor isoform, the association rate constant (kon) is typi-
cally slow. In contrast, when conformational changes fol-
low binding, which is referred to as induced fit, the kon is
less likely to be slow. The slow kon measured for TCR–
pMHC interactions is evidence that, at least in some cases,
these conformational changes precede TCR binding (41,
58, 59). It is also possible that conformational changes fol-
low initial TCR engagement, as has been proposed by Wu
et al. (60), but direct evidence for this is lacking. To inves-
tigate when the conformational change that we had identi-
fied occurred, we undertook a detailed kinetic and thermo-
dynamic analysis of a TCR binding to these peptide
variants. We expressed and purified a soluble form of the
G10 TCR and tested this for binding to HLA-A2 present-
ing either SLFNTVATL or SLYNTVATL. Binding was
measured at temperatures from 5 to 37 C. From the data,
we determined thermodynamic and kinetic parameters for
these interactions (Fig. 6 and Table II). If conformational
changes preceded binding, we would have expected there
to be differences in the association kinetics given that one
of the peptides would have to undergo a substantial change
before binding. However, in both cases, association fol-
Figure 6. Binding of clone G10 TCR to HLA-A2–SLFNTVATL and
HLA-A2–SLYNTVATL. (A) Measurement of affinity. Soluble G10
TCR was injected at the indicated concentrations over surfaces onto
which  1,000 RU of HLA-A2–SLFNTVATL or HLA-A2–SLYNTVATL
were immobilized and the level of binding reached at equilibrium was
recorded. The lines are fits of the simple 1:1 binding model that yielded
affinities of Kd 5.2  M and 2.2  M for HLA-A2–SLFNTVATL (circles)
and HLA-A2–SLYNTVATL (squares), respectively. (inset) Scatchard
transformation of the same data. (B) van’t Hoff analysis. Affinities (con-
verted to  G  as in Table II) were measured over a range of temperatures.
The curves show fits of the nonlinear van’t Hoff equation to the data.
These fits were used to determine the  H,  T S, and  C values shown
in Table II. (C) Kinetic analysis. The indicated concentrations of G10
TCR were injected over HLA-A2–SLYNTVATL (black lines). A simul-
taneous global fit of equations derived from the simple 1:1 binding model
is shown (red). This yielded a kon of 24900 M 1.s 1 and a koff of 0.064 s 1.
(D) Eyring plot of kon measured at different temperatures. The slope and
intercept of linear fits to the data (red lines) were used to determine
 ‡Hon and T ‡Son, respectively (Table II).
Table II. Summary of Binding Data
Parametera SLFNTVATL SLYNTVATL
Kd ( M)b 5.2   0.5 2.2   0.5
kon (M 1.s 1) 34,000   3,000 33,000   5,000
koff (s 1) 0.16   0.002 0.06   0.001
 G c  7.2  7.7
 Hd  10.4   0.4  10.5   0.4
 T Sd 3.2   0.5 2.8   0.4
 C (kcal.M 1.K 1) 0.62   0.05 0.63   0.05
 ‡Hon
e 12.5   0.6 13.7   0.7
 T ‡Son
e  1.1   0.7  2.4   0.7
aAll parameters were measured/calculated at 25°C (298.15 K) and ex-
pressed in kcal.M 1 unless otherwise indicated. Unless otherwise indi-
cated, values shown are mean   SEM (n   3). 
bMeasured by equilibrium binding analysis (Fig. 6 A).
c G    R.T.lnKd, where R is the gas constant and Kd is the equilib-
rium dissociation constant expressed in units M.
dDetermined by van’t Hoff analysis (Fig. 6 B). Values are mean   SE
of fit.
eDetermined by Eyring analysis (Fig. 6 D). Values are mean   SE of fit.Lee et al. 1463
lowed pseudo–first order kinetics and the kons were indis-
tinguishable. Nor were any differences detected in the acti-
vation enthalpy ( ‡Hon) and entropy changes (T ‡Son) that
accompany association. The G10 TCR dissociated more
slowly from the HLA-A2–SLYNTVATL complex, result-
ing in an approximately twofold higher affinity. To con-
firm that the kons were similar for HLA-A2–SLFNTVATL
and HLA-A2–SLYNTVATL under conditions nearest to
the crystallization conditions, we measured binding at 50
mM MES, pH 6.5, with no NaCl present. Association rate
constants under these conditions were essentially identical,
despite the large differences observed in the two peptide-
HLA-A2 crystal structures at these conditions. Therefore,
our analysis of the association kinetics suggests that no en-
ergetically significant conformational changes in the pep-
tide occur before formation of the transition state complex.
This implies that conformational changes follow formation
of the transition state, supporting an induced fit mechanism
of conformational change.
Discussion
Our results make two important and related points. First,
the data show the exquisite functional specificity of CD8  T
cells, with different receptors from chronically HIV-infected
patients, to variants of this immunodominant epitope. Sec-
ond, we provide evidence in support of an induced fit
mechanism of TCR binding, whereby large conformational
changes in the peptide follow initial TCR engagement.
Whether CD8  T cells cross-react with virus variants is a
very important issue in infection with HIV and other vari-
able viruses. Failure of T cells to recognize variants gives
the chronically replicating virus multiple chances to escape
from immune control. Here, we show that for a clinically
relevant epitope, two thirds of random mutations are not
recognized. Although much has been made of cross-reac-
tive T cells in the arena of vaccine design, our data are in
line with earlier studies on peptide variants of influenza ma-
trix peptide presented by HLA-A2, HTLV-1 tax peptide
presented by HLA-A2 and EBV EBNA-3 peptide pre-
sented by HLA-B8 (9–11). Therefore, T cell responses to
pathogenic viruses appear very sensitive to epitope change.
However, Mason (61) has argued that because the T cell
receptor repertoire is limited by the total number of T cells
in the body, yet responds to all pathogens, each receptor
must be able to see many different peptides presented by
the same MHC molecule. Indeed, there are well-known
examples of T cell clones cross-reacting on different
MHC–peptide complexes (3, 4), but the specific set of
binding interactions made by the TCR to each of these
peptide–MHCs must be different (56, 62) and we would
expect each binding mode to be just as sensitive to variants
of the relevant peptide. Thus, the paradox of the same
TCR showing significant cross-reactivity, but also very fine
specificity for recognition of a single epitope, can be re-
solved. For a minority of variant peptides, binding to the
MHC is so impaired that the epitope fails to present. Most
well-described escape mutations of HIV are of this type
(13–18, 50) and such mutations reach fixation. However,
we show here that most variant peptides still bind HLA-A2,
but most are not recognized by T cells. Given that T cells
can react to very low numbers of presented peptides on a
cell (44, 45), this finding implies that the majority of ran-
domly generated epitope mutations affect the interaction
between TCR and bound peptide. Priming of new T cell
clones could deal with the problem, but in ongoing HIV
infection the capacity to make new primary T cell re-
sponses may be impaired (22), possibly because of damage
to dendritic cells or T helper cells. If we can generalize
from our findings concerning a dominant HIV epitope, and
from previous studies of this type, the implication is that a
T cell response to HIV that fails to suppress virus replication
sufficiently is doomed to select escape mutants. The dem-
onstration that the HLA type of an infected person shapes
the virus sequence is powerful support for this concept (63).
One surprising finding in our structure–function analysis
was that the apparently small variation in the epitope from
SLFNTVATL to SLYNTVATL (a common mutation in
vivo that is cross-recognized by many T cells) causes a ma-
jor difference in structure. Yet the observed T cell cross-
reactivity implies that one conformation, common to
SLFNTVATL and SLYNTVATL, is recognized by the
TCRs. This interpretation is strongly supported by the very
similar patterns of T cell recognition for variants of the two
peptides in which single amino acid changes are made to
residues in the conformationally different regions. If pep-
tides with either conformation pre–TCR-binding change
to a single common conformation on TCR binding, the
additional changes in peptide sequence would be sampled
in essentially identical contexts. The alternative explana-
tion, that both TCRs recognize two very different peptide
structures and that many changes in the structurally distinct
portions (P5-P6) of these peptides coincidently all have the
identical effect on TCR recognition, is highly implausible.
It follows that at least one of the peptides must undergo a
substantial conformational change during TCR binding.
Some previous observations support this hypothesis. Crystal
structures of HLA-A2 HTLV-1 Tax epitope in complex
with two different TCRs show a significant and identical
change in the peptide conformation on comparison of the
pMHC and TCR–pMHC structures (52, 64). In that case,
the change in peptide conformation at P5-P6 rotated both
side chains by  90  on TCR binding. A subsequent series
of crystal structures for TCR–pMHC complexes of altered
peptide ligands also preserved the same TCR bound pep-
tide conformation (65). Clearly, the balance of interactions
that determine the conformation of the central portion of
the peptide in at least some pMHCs can be altered in re-
sponse to TCR binding. For SLFNTVATL and SLYNT-
VATL kinetic analysis revealed, somewhat unexpectedly,
that the kons (and the  ‡Hon) of TCR binding the two pep-
tide complexes were indistinguishable. Because significant
conformation adjustment of the peptide would result in
significant differences in the kon and/or  ‡Hon, this implies
that energetically significant conformational adjustments
are not occurring before formation of the transition stateFine Specificity of HIV-specific T Cells 1464
complex. This means that the conformational changes
probably occur as the transition state complex relaxes into
the final complex. An unlikely alternative explanation for
the identical kinetics is that both peptides change into a
third common conformation in the transition state, and
that, by coincidence, both conformational changes have
identical energetic barriers.
All interacting molecules, including the TCR–pMHC
complex form a high-energy transition state complex (66)
before relaxing into the final complex, and Wu et al. (60)
showed that the TCR forms contact with residues on the
MHC  -helices in the transition state complex. They were
unable to rule out formation of contacts with peptides in
the transition state, but it was clear that TCR forms these
in the final complex. Based on these findings, and structural
studies of other TCR–pMHC systems, which provide clear
evidence of conformational change upon binding, Wu et
al. proposed that the TCR initially forms contacts with the
MHC in the transition state, and that after this there is a
conformational change of the TCR CDR3 loops and for-
mation of contacts with peptide (60). However, they pro-
vided no direct evidence for this induced fit mechanism
and their data are also consistent with a preexisting equilib-
rium mechanism (57), whereby conformational changes
precede TCR binding to pMHC. Indeed, the very slow
kon of many TCR–pMHC interactions (59), including the
2B4 TCR system studied by Wu et al., strongly suggests
that conformation changes often precede formation of the
transition state. Recently, Gakamsky et al. (67) pointed out
that published kinetic and structural data to date do not al-
low one to distinguish between the two main mechanisms
of conformational change at the TCR–pMHC interface.
In contrast, the data presented here provide evidence
that conformational changes at the TCR–pMHC binding
interface can occur after formation of the transition state
complex (Fig. 7). These findings support the proposal by
Wu et al. that the TCR first docks on MHC molecules rel-
atively independently of the peptide, followed by confor-
mational adjustments as the TCR and peptide–MHC relax
from the transition state into the final complex. The stabil-
ity of the final complex and, therefore, TCR triggering
will be very sensitive to epitope sequence variation.
In conclusion, these studies give some insight into how
initial TCR contact can be quite cross-reactive, but tran-
sient. If TCR and peptide–MHC can adjust conformation
to fit each other, more stable binding occurs and the T cell
is triggered. However, this phase of T cell activation is
highly specific with minimal scope for cross-reactivity.
Such fine specificity may protect the host from autoim-
mune reactions but a penalty is paid when a virus can per-
sist and is poorly controlled, as replication and mutation
will lead to frequent immune escape. For vaccine design,
the susceptibility of T cells to virus variation is of immense
importance (24, 25). Unless vaccines can stimulate very
broad T cell responses specific for multiple epitopes, it is
unlikely that vaccines that are based on one subtype will
offer significant protection against another subtype of HIV
where the proteins differ by 20–30% (i.e., more than one
amino acid change per epitope). Even within subtypes,
there is enough variation ( 5%) to cause concern.
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